News
Restore Vision, one of Remiges' portfolio companies, announced the first patient dosed in Phase I/II clinical trial of RV-001 for gene-agnostic retinitis pigmentosa
Restore Vision, one of Remiges' portfolio companies, announced the first patient dosed in Phase I/II clinical trial of RV-001 for gene-agnostic retinitis pigmentosa
02/13/2025
----------Quote from the Company’s Website—————
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
・The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans.
・RV-001 starting dose was generally well tolerated in this open-label trial.
・RV-001 a gene-agnostic approach for RP patients.
Tokyo, Japan, February 13, 2025 - Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed at Keio University Hospital.
Phase I/II Safety, Tolerability, and Exploratory Efficacy Trial Highlights
- Patient Criteria: Participants with advanced RP, agnostic to genotype, and characterized by severe vision loss, no- to limited vision.
- Safety and Efficacy: In addition to safety, exploratory efficacy endpoints include improvements in light sensitivity and visual function.
For further details, please check the press release below.
PR Newswire
----------unquote—————
For more detailed information please visit the above web page